Large study for individually adapted dietary advice carried out by self-sampling with Capitainer
Chalmers University of Technology is currently conducting SCAPIS2-HOME, a groundbreaking study in precision nutrition. The goal is to understand how people react to meals to build knowledge on how individually tailored dietary advice can be designed to prevent diseases such as heart attacks and strokes. The study uses Capitainer's sampling card Capitainer®B50, after winning a public tender, to enable self-sampling.
SCAPIS is a globally unique study, financed by the Swedish Heart Lung Foundation, with a focus on the heart, vessels and lungs. The study has been ongoing for over 10 years and involves over 30,000 randomly selected individuals. The new sub-study SCAPIS2-HOME includes 4,400 participants in Gothenburg and Umeå, investigating how people react differently to the same meals, to identify new biomarkers in the blood linked to long-term health.
Self-sampling allows participants to perform all steps at home, simplifying the process both for individuals and the study's implementation. Capitainer's technology enables blood samples to be taken with the same accuracy as in healthcare settings, allowing researchers to analyze hundreds of different blood markers.
"This is groundbreaking because, for the first time, we will have the opportunity to directly link how different individuals react to meals — also focusing on long-term health outcomes. The advantage of this study is the extensive and sophisticated investigations into heart and vascular health and lung function which will be conducted, to which our meal outcomes can be linked," says Rikard Landberg, Professor of Food and Nutrition Science.
"This research demonstrates the potential of self-sampling and Capitainer's blood sampling solution. It offers the opportunity to conduct large scientific studies more efficiently and with the participants in focus. We are very pleased with the collaboration with Chalmers and that our products can contribute to new knowledge and hopefully preventive measures for major public health issues," says Christopher Aulin, CEO of Capitainer.
More about the study
SCAPIS2-HOME is part of an extensive research effort on precision nutrition that started in January 2024. The study is led by Professor Rikard Landberg at Chalmers University of Technology and includes international collaborations with researchers from Harvard and MIT. The goal is to identify biomarkers that can indicate how different individuals respond to specific diets, which can lead to more effective and customized dietary advice. The study builds on previous successes within the SCAPIS project, where researchers investigate how lifestyle changes can prevent diseases such as diabetes, cardiovascular disease and certain forms of cancer. More information about the study is available at Chalmers.
For more information, please contact:
Christopher Aulin, CEO
Phone: +46 (0)708 977577
Email: christopher.aulin@capitainer.com
About Capitainer
Capitainer AB is a Swedish MedTech company that develops and sells patient-centric solutions for self-sampling of blood, plasma, and urine. Founded in 2016, Capitainer has developed unique technologies for collecting and drying exact volumes of fluid within easy-to-use sampling cards. These cards may be sent as standard post to relevant testing laboratories, thus bypassing the need for cold chain logistics and specialised packaging. Capitainer’s products are market-leading with respect to precision and accuracy, with demonstrated equal performance to established pipetting methods. The products are applicable within several market segments, including but not limited to, clinical biomarkers, therapeutic drug monitoring, genomics, drug abuse and doping testing, and R&D and clinical studies.
Tags:
